Ousia Pharma
Innovative peptide drug conjugates targeting obesity and metabolic diseases with sustained weight loss and safety.
| Date | Investors | Amount | Round |
|---|---|---|---|
| investor | €0.0 | round | |
| N/A | €0.0 | round | |
| investor | €0.0 | round | |
* | N/A | Seed | |
| Total Funding | 000k | ||
| DKK | 2022 | 2023 | 2024 |
|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 |
| EBITDA | 0000 | 0000 | 0000 |
| Profit | 0000 | 0000 | 0000 |
| EV | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 |
Source: Company filings or news article
Related Content
Ousia Pharma ApS is a Danish biotechnology startup specializing in the development of novel peptide drug conjugates aimed at treating obesity and metabolic diseases. The company operates in the biopharmaceutical sector, focusing on leveraging its unique discovery in neurobiology to address the challenges of obesity treatment. Ousia Pharma's core product involves engineered peptide NMDAR antagonist drug conjugates designed to deliver modulators of synaptic plasticity to the brain. This approach aims to achieve potent and sustained weight loss without compromising patient safety. The company's business model revolves around research and development, with a focus on bringing innovative therapeutic solutions to market. Revenue is generated through the development and potential commercialization of these novel drug candidates, targeting healthcare providers and patients suffering from obesity and related metabolic disorders.
Keywords: peptide drug conjugates, obesity treatment, metabolic diseases, NMDAR antagonists, synaptic plasticity, weight loss, biotechnology, neurobiology, Danish startup, biopharmaceutical.